153 related articles for article (PubMed ID: 30733425)
1. Lipid analysis in an aging population.
Pallazola VA; Sathiyakumar V; Martin SS
Aging (Albany NY); 2019 Feb; 11(4):1073-1074. PubMed ID: 30733425
[No Abstract] [Full Text] [Related]
2. Lipid lowering in high-risk populations: how low should we go?
Watson K
Ethn Dis; 2001; 11(4):834-7. PubMed ID: 11763308
[No Abstract] [Full Text] [Related]
3. Hyperlipidemia in Native Americans: evaluation of lipid management through a cardiovascular risk reduction program.
Burden RW; Kumar RN; Phillips DL; Borrego ME; Galloway JM
J Am Pharm Assoc (Wash); 2002; 42(4):652-5. PubMed ID: 12150364
[No Abstract] [Full Text] [Related]
4. Hyperlipidaemia and cardiovascular disease.
Buchalter M
Curr Opin Lipidol; 1997 Jun; 8(3):U40-1. PubMed ID: 9211073
[No Abstract] [Full Text] [Related]
5. Analysis of the lipid profile of elderly women in Curitiba - Parana.
Krause MP; Hallage T; Miculis CP; Gama MP; Silva SG
Arq Bras Cardiol; 2008 May; 90(5):299-304. PubMed ID: 18516398
[TBL] [Abstract][Full Text] [Related]
6. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
7. Trends in lipids and lipoproteins in US adults, 1988-2010.
Carroll MD; Kit BK; Lacher DA; Shero ST; Mussolino ME
JAMA; 2012 Oct; 308(15):1545-54. PubMed ID: 23073951
[TBL] [Abstract][Full Text] [Related]
8. Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides.
Nerbrand C; Nyberg P; Nordström L; Samsioe G
Maturitas; 2002 May; 42(1):55-62. PubMed ID: 12020980
[TBL] [Abstract][Full Text] [Related]
9. Non-high-density lipoprotein cholesterol: an alternate target for lipid-lowering therapy.
Bittner V
Prev Cardiol; 2004; 7(3):122-6; quiz 129-30. PubMed ID: 15249764
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial.
Martin SS; Giugliano RP; Murphy SA; Wasserman SM; Stein EA; Ceška R; López-Miranda J; Georgiev B; Lorenzatti AJ; Tikkanen MJ; Sever PS; Keech AC; Pedersen TR; Sabatine MS
JAMA Cardiol; 2018 Aug; 3(8):749-753. PubMed ID: 29898218
[TBL] [Abstract][Full Text] [Related]
11. Use of simvastatin treatment in patients with combined hyperlipidemia in clinical practice. For the Simvastatin Combined Hyperlipidemia Registry Group.
Vicari RM; Wan GJ; Aura AM; Alexander CM; Markson LE; Teutsch SM
Arch Fam Med; 2000; 9(9):898-905. PubMed ID: 11031398
[TBL] [Abstract][Full Text] [Related]
12. Editorial: reducing cardiovascular risk: is low-density lipoprotein-cholesterol (LDL-C) lowering enough?
Kostapanos MS; Katsiki N; Elisaf MS; Mikhailidis DP
Curr Vasc Pharmacol; 2012 Mar; 10(2):173-7. PubMed ID: 22250844
[No Abstract] [Full Text] [Related]
13. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug.
Aronow WS; Ahn C
Am J Cardiol; 2002 Jul; 90(2):147-9. PubMed ID: 12106845
[No Abstract] [Full Text] [Related]
14. [Update: clinical lipidology].
Parhofer KG
MMW Fortschr Med; 2013 Jul; 155(13):49-52; quiz 53-4. PubMed ID: 23964509
[No Abstract] [Full Text] [Related]
15. Reaching low density lipoprotein cholesterol targets.
Rizos CV; Barkas F; Elisaf MS
Curr Med Res Opin; 2014 Oct; 30(10):1967-9. PubMed ID: 25055191
[TBL] [Abstract][Full Text] [Related]
16. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management.
Assmann G
Am J Cardiol; 2001 Mar; 87(5A):2B-7B. PubMed ID: 11256848
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 inhibition - a novel mechanism to treat lipid disorders?
Banach M; Rizzo M; Obradovic M; Montalto G; Rysz J; Mikhailidis DP; Isenovic ER
Curr Pharm Des; 2013; 19(21):3869-77. PubMed ID: 23286435
[TBL] [Abstract][Full Text] [Related]
18. Hypolipidemic effect of Glycine tomentella root extract in hamsters.
Ko YJ; Wu YW; Lin WC
Am J Chin Med; 2004; 32(1):57-63. PubMed ID: 15154285
[TBL] [Abstract][Full Text] [Related]
19. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
[TBL] [Abstract][Full Text] [Related]
20. Hypolipidemic drugs in coronary artery disease.
Bittar GB
Ann Intern Med; 1997 Jun; 126(11):916-7. PubMed ID: 9163300
[No Abstract] [Full Text] [Related]
[Next] [New Search]
